{"entity":{"id":"orm-6151","kind":"drug","name":"ORM-6151 (BMS-986497)","aka":["ORM-6151","BMS-986497"],"tldr":"ORM-6151 (BMS-986497) is a degrader-antibody conjugate from Orum Therapeutics that reached phase 1 for relapsed or refractory acute myeloid leukaemia and myelodysplastic syndrome; development has stopped.","summary":"ORM-6151 (BMS-986497) (ORM-6151, BMS-986497) is a degrader-antibody conjugate from Orum Therapeutics, with Bristol Myers Squibb as acquirer. A CD33-directed antibody carrying a GSPT1-degrading payload, for acute myeloid leukaemia and high-risk MDS. Its furthest stage is phase 1, for relapsed or refractory acute myeloid leukaemia and myelodysplastic syndrome. ClinicalTrials.gov registers it in one study linked below. BMS's phase 1 NCT06419634 is TERMINATED ('Inability to meet protocol objectives', 28 August 2026). A Korean news report of 19 September 2026 says BMS discontinued development and returned the rights to Orum. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Orum Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT06419634"},{"label":"Orum Therapeutics: v.daum.net","url":"https://v.daum.net/v/20260919074351390"},{"label":"ClinicalTrials.gov: trials of ORM-6151","url":"https://clinicaltrials.gov/search?intr=ORM-6151"}],"tags":["pipeline","ctgov-ingest","discontinued"],"related":[],"cancers":["aml","mds"],"sections":[],"technologies":[],"targets":["cd33"],"drugs":[],"companies":["orum-therapeutics","bms"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06419634"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"ORM-6151","modality":"Degrader-antibody conjugate","mechanism":"A CD33-directed antibody carrying a GSPT1-degrading payload, for acute myeloid leukaemia and high-risk MDS.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/orm-6151/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"target":[{"id":"cd33","kind":"target","name":"CD33","route":"/targets/cd33/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"},{"id":"orum-therapeutics","kind":"company","name":"Orum Therapeutics","route":"/companies/orum-therapeutics/"}],"trial":[{"id":"nct06419634","kind":"trial","name":"Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","route":"/trials/nct06419634/"}]}}